PEB: Positive Results in Kaiser Permanente User Programme, page-17

Not all of the statistics are disclosed here however it would seem that cx bladder has found an important  niches in the clinic.

Those looking for a magic bullet to completely replaces cystoscopy may be disappointed.  Those looking for an adjunct test that  reduces the required frequency and cost of cystoscopy examinations (e.g. patients and hospital accountants and those clinicians that don't use unnecessary cystoscopy to stay rich) will be very happy IMHO.

The other niche clinical applicaton is to identify the possibility of upper urinary tract cancers that may be missed by cystoscopy .  

All will be revealed to the global urologist community soon as we await KP's commercial decision.

cheers